Sana Biotechnology ups IPO to 22M shares at $23–$24, targeting ~$517M at midpoint after $700M+ VC funding

Sana Biotechnology raised its IPO target to 22 million shares at $23–$24 each, expecting about $517 million at the midpoint, after previously aiming much lower and following over $700 million in venture funding. The Seattle gene- and cell-therapy startup plans near-term cancer treatments and broader goals to modify any gene or replace damaged cells.

SSteve Harr SSana Biotechnology